Cargando…
Hereditary cancer screening: Case reports and review of literature on ten Ashkenazi Jewish founder mutations
BACKGROUND: Historically, three founder mutations in the BRCA1/2 (OMIM 113705; OMIM 600185) genes have been the focus of cancer risks within the Ashkenazi Jewish (AJ) population. However, there are several additional mutations associated with increased susceptibility to cancer in individuals of AJ a...
Autores principales: | Cox, Devin M., Nelson, Katherine L., Clytone, Meera, Collins, Debra L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6305650/ https://www.ncbi.nlm.nih.gov/pubmed/30152102 http://dx.doi.org/10.1002/mgg3.460 |
Ejemplares similares
-
How old is this mutation? - a study of three Ashkenazi Jewish founder mutations
por: Greenwood, Celia MT, et al.
Publicado: (2010) -
Founder mutations in BRCA1/2 are not frequent in Canadian Ashkenazi Jewish men with prostate cancer
por: Hamel, Nancy, et al.
Publicado: (2003) -
Identifying Ashkenazi Jewish BRCA1/2 founder variants in individuals who do not self-report Jewish ancestry
por: Tennen, Ruth I., et al.
Publicado: (2020) -
Carrier screening in individuals of Ashkenazi Jewish descent
por: Gross, Susan J., et al.
Publicado: (2008) -
BRCA1 and BRCA2 Mutations Other Than the Founder Alleles Among Ashkenazi Jewish in the Population of Argentina
por: Solano, Angela R., et al.
Publicado: (2018)